Astute Medical receives $30M from funding partner

Astute Medical will receive $30 million from funding partner CRG. The funds will go towards commercialization of the diagnostic NephroCheck Test System for acute kidney injury, and an additional $10 million will become available to Astute when it achieves certain preset revenue milestones. The FDA recently cleared the system and give its stamp of approval for Astute to start selling the product to the public. Release

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.